| 產品名稱 | Panc 10.05 |
|---|---|
| 商品貨號 | B165484 |
| Organism | Homo sapiens, human |
| Tissue | pancreas |
| Cell Type | epithelial |
| Product Format | frozen |
| Morphology | epithelial |
| Culture Properties | adherent |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | adenocarcinoma |
| Age | adult |
| Gender | male |
| Ethnicity | Caucasian |
| Storage Conditions | liquid nitrogen vapor phase |
| Images |  |
| Derivation | Panc 10.05 is a pancreatic adenocarcinoma epithelial cell line derived in 1992 from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma. The Panc 10.05 cell line was derived from the same patient as the PL45 cell line (ATCC CRL-2558). |
| Clinical Data | adult
male
|
| Antigen Expression | MHC class I +; MHC class II - |
| Oncogene | K-ras +
Ref  Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |
| Genes Expressed | cytokeratins 7 and 18
Ref
Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |
| Cellular Products | cytokeratins 7 and 18
Ref Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |
| Tumorigenic | Yes |
| Effects | Yes, forms tumors in nude or SCID mice |
| Comments | Both the PL45 and the Panc 10.05 cell lines exhibit a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine.
The cells have a reported plating efficiency of 40%.
|
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium:
|
| Subculturing | Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Subculture Ratio: 1:2 to 1:4 Medium Renewal: Every 2 to 3 days.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994. |
| Cryopreservation | Freeze Medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage Temperature: Liquid nitrogen vapor phase |
| Culture Conditions | Temperature: 37°C |
| STR Profile | D5S818: 13 D13S317: 12 D7S820: 8,9 D16S539: 9,12 vWA: 16 THO1: 6,9.3 Amelogenin: X TPOX: 11 CSF1PO: 12 |
| Population Doubling Time | 19.2 hrs |
| Name of Depositor | EM Jaffee |
| Deposited As | human |
| Year of Origin | 1992 |
| References | Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
